Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Penter L, Liu Y, Wolff JO, Yang L, et al. Blood 2023;141:1817-1830.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Penter L, Liu Y, Wolff JO, Yang L, et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood 2023;141:1817-1830.
PMID: 36706355